FINAZZI, MARIA CHIARA
FINAZZI, MARIA CHIARA
Dipartimento di Oncologia ed Emato-Oncologia
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes
2024 T. Barbui, A. Carobbio, V. De Stefano, A. Alvarez-Larran, A. Ghirardi, G. Carioli, F. Fenili, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, L. Calabresi, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Ramundo, F. Lunghi, L. Scaffidi, C. Bucelli, D. Cattaneo, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi, A.M. Vannucchi
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera
2023 T. Barbui, A.M. Vannucchi, V. De Stefano, A. Carobbio, A. Ghirardi, G. Carioli, A. Masciulli, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G.G. Loscocco, P. Guglielmelli, F. Gesullo, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer
2023 T. Barbui, A. Gavazzi, E. Sciatti, M.C. Finazzi, A. Ghirardi, G. Carioli, A. Carobbio
Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
2023 G. Ortí, L. Gras, N. Zinger, M.C. Finazzi, K. Sockel, M. Robin, E. Forcade, D. Avenoso, N. Kröger, J. Finke, A. Radujkovic, M. Hunault-Berger, W. Schroyens, T. Zuckerman, J.H. Bourhis, Y. Chalandon, A. Bloor, R. Schots, L.C. de Wreede, J. Drozd-Sokolowska, K. Raj, N. Polverelli, T. Czerw, J.C. Hernández-Boluda, D. Mclornan, I. Yakoub-Agha
Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT
2023 J.C. Hernández-Boluda, D. Eikema, L. Koster, N. Kröger, M. Robin, M. de Witte, J. Finke, M.C. Finazzi, A. Broers, L. Raida, N. Schaap, P. Chiusolo, M. Verbeek, C.L.E. Hazenberg, K. Halaburda, A. Kulagin, H. Labussière-Wallet, T. Gedde-Dahl, W. Rabitsch, K. Raj, J. Drozd-Sokolowska, G. Battipaglia, N. Polverelli, T. Czerw, I. Yakoub-Agha, D.P. Mclornan
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
2022 T. Barbui, A. Ghirardi, A. Carobbio, A. Masciulli, G. Carioli, A. Rambaldi, M.C. Finazzi, M. Bellini, E. Rumi, D. Vanni, O. Borsani, F. Passamonti, B. Mora, M. Brociner, P. Guglielmelli, C. Paoli, A. Alvarez-Larran, A. Triguero, M. Garrote, H. Pettersson, B. Andréasson, G. Barosi, A.M. Vannucchi
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: Update of the ERNEST Study
2022 P. Guglielmelli, A. Ghirardi, A. Carobbio, A. Masciulli, C. Maccari, B. Mora, E. Rumi, A. Triguero, M.C. Finazzi, H. Pettersson, C. Paoli, F. Mannelli, D. Vanni, A. Rambaldi, F. Passamonti, A. Alvarez-Larran, B. Andreasson, A.M. Vannucchi, T. Barbui
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
2022 M. Maffioli, B. Mora, S. Ball, A. Iurlo, E.M. Elli, M.C. Finazzi, N. Polverelli, E. Rumi, M. Caramella, M.C. Carraro, M. D'Adda, A. Molteni, C. Sissa, F. Lunghi, A. Vismara, M. Ubezio, A. Guidetti, S. Caberlon, M. Anghilieri, R.S. Komrokji, D. Cattaneo, M.G. Della Porta, T. Giorgino, L. Bertù, M. Brociner, A.T. Kuykendall, F. Passamonti
Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma
2021 E. Derenzini, V. Tabanelli, S. Sammassimo, S. Mazzara, G. Motta, F. Melle, A. Vanazzi, A. Calleri, S. Fiori, M.C. Finazzi, M.C. Barbanti, S. Ramadan, S. Gandini, R. Pastano, A. Rambaldi, S. Pileri, C. Tarella
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial
2021 T. Barbui, A.M. Vannucchi, V. De Stefano, A. Masciulli, A. Carobbio, A. Ferrari, A. Ghirardi, E. Rossi, F. Ciceri, M. Bonifacio, A. Iurlo, F. Palandri, G. Benevolo, F. Pane, A. Ricco, G. Carli, M. Caramella, D. Rapezzi, C. Musolino, S. Siragusa, E. Rumi, A. Patriarca, N. Cascavilla, B. Mora, E. Cacciola, C. Mannarelli, G.G. Loscocco, P. Guglielmelli, S. Betti, F. Lunghi, L. Scaffidi, C. Bucelli, N. Vianelli, M. Bellini, M.C. Finazzi, G. Tognoni, A. Rambaldi
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
2020 P. Guglielmelli, A. Carobbio, E. Rumi, V. De Stefano, L. Mannelli, F. Mannelli, G. Rotunno, G. Coltro, S. Betti, C. Cavalloni, M.C. Finazzi, J. Thiele, M. Cazzola, A.M. Vannucchi, T. Barbui
Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival
2020 M.C. Finazzi, C. Boschini, C. Craddock, A. Rambaldi, J. Ward, R.K. Malladi
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
2020 A. Carobbio, P. Guglielmelli, E. Rumi, C. Cavalloni, V. De Stefano, S. Betti, A. Rambaldi, M.C. Finazzi, J. Thiele, A.M. Vannucchi, A. Tefferi, T. Barbui
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
2019 A. Yacoub, J. Mascarenhas, H. Kosiorek, J.T. Prchal, D. Berenzon, M.R. Baer, E. Ritchie, R.T. Silver, C. Kessler, E. Winton, M.C. Finazzi, A. Rambaldi, A.M. Vannucchi, D. Leibowitz, D. Rondelli, M.O. Arcasoy, R. Catchatourian, J. Vadakara, V. Rosti, E. Hexner, M. Kremyanskaya, L. Sandy, J. Tripodi, V. Najfeld, N. Farnoud, E. Papaemmanuil, M. Salama, R. Singer-Weinberg, R. Rampal, J.D. Goldberg, T. Barbui, R. Mesa, A.C. Dueck, R. Hoffman
Second primary malignancies in ruxolitinib-treated myelofibrosis : real-world evidence from 219 consecutive patients
2019 M. Maffioli, T. Giorgino, B. Mora, A. Iurlo, E. Elli, M.C. Finazzi, M. Caramella, E. Rumi, M.C. Carraro, N. Polverelli, M. D'Adda, S. Malato, M. Rossi, A. Molteni, A. Vismara, C. Sissa, F. Spina, M. Anghilieri, D. Cattaneo, R. Renso, M. Bellini, M.L. Pioltelli, C. Cavalloni, D. Barraco, R. Accetta, L. Bertu, M.G.D. Porta, F. Passamonti
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
2019 J. Mascarenhas, H. Kosiorek, J. Prchal, A. Yacoub, D. Berenzon, M.R. Baer, E. Ritchie, R.T. Silver, C. Kessler, E. Winton, M.C. Finazzi, A. Rambaldi, A.M. Vannucchi, D. Leibowitz, D. Rondelli, M.O. Arcasoy, R. Catchatourian, J. Vadakara, V. Rosti, E. Hexner, M. Kremyanskaya, L. Sandy, J. Tripodi, V. Najfeld, N. Farnoud, M.E. Salama, R.S. Weinberg, R. Rampal, J.D. Goldberg, R. Mesa, A.C. Dueck, R. Hoffman
Busulfan or thiotepa based conditioning in myelofibrosis: A phase II multicenter randomized study from the GITMO group
2019 F. Patriarca, A. Masciulli, A. Bacigalupo, S. Bregante, C. Pavoni, M.C. Finazzi, A. Bosi, D. Russo, F. Narni, G. Messina, E.P. Alessandrino, A.M. Carella, G. Milone, B. Bruno, S. Mammoliti, B. Bruno, R. Fanin, F. Bonifazi, A. Rambaldi
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
2018 A. Tefferi, M. Mudireddy, F. Mannelli, K.H. Begna, M.M. Patnaik, C.A. Hanson, R.P. Ketterling, N. Gangat, M. Yogarajah, V. De Stefano, F. Passamonti, V. Rosti, M.C. Finazzi, A. Rambaldi, A. Bosi, P. Guglielmelli, A. Pardanani, A.M. Vannucchi
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
2018 V. De Stefano, A. Carobbio, V. Di Lazzaro, P. Guglielmelli, A. Iurlo, M.C. Finazzi, E. Rumi, F. Cervantes, E.M. Elli, M.L. Randi, M. Griesshammer, F. Palandri, M. Bonifacio, J.-. Hernandez-Boluda, R. Cacciola, P. Miroslava, G. Carli, E. Beggiato, M.H. Ellis, C. Musolino, G. Gaidano, D. Rapezzi, A. Tieghi, F. Lunghi, G.G. Loscocco, D. Cattaneo, A. Cortelezzi, S. Betti, E. Rossi, G. Finazzi, B. Censori, M. Cazzola, M. Bellini, E. Arellano-Rodrigo, I. Bertozzi, P. Sadjadian, N. Vianelli, L. Scaffidi, M. Gomez, E. Cacciola, A.M. Vannucchi, T. Barbui
Detection of driver and subclonal mutations in myelofibrosis : clinical impact on pharmacologic and transplant based treatment strategies
2017 M.C. Finazzi, F. Lussana, S. Salmoiraghi, O. Spinelli, A. Rambaldi